Research programme: amyloid disorder therapies - TheraCarbAlternative Names: AMY
Latest Information Update: 06 Dec 2010
At a glance
- Originator TheraCarb
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyloid A amyloidosis
Most Recent Events
- 04 Feb 2007 Preclinical trials in Amyloidosis in Canada (unspecified route)
- 04 Feb 2007 Preclinical trials in Alzheimer's disease in Canada (unspecified route)